Cadrenal Therapeutics Q3 2024 cash $11.3M, raises $9.8M from ATM and warrants

Cadrenal Therapeutics, Inc.

2024-Q3 EPS reported -$5.99

Q3 2024 operating expenses $2.5M including $0.3M non-cash; cash used in operations $2.2M.
Raised $5.1M via ATM and $4.7M from warrant exercises, totaling $9.8M.
FDA discussions advancing on tecarfarin Phase 3 LVAD trial protocol; Abbott collaboration ongoing.
CDMO completed readiness to supply API and clinical trial materials under cGMP.
Joined Anticoagulation Forum Corporate Council to engage 15,000 healthcare professionals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.